Drug intelligence / Profile preview

PF-07258669

Development stage: Phase 1
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral

Overview

PF-07258669 is an orally available small molecule drug developed by Pfizer. It acts as a selective antagonist of the melanocortin-4 receptor (MC4R), a G protein-coupled receptor involved in regulating energy homeostasis and somatic growth. By blocking MC4R, PF-07258669 is intended to increase appetite and promote weight gain, making it a potential treatment for unintended weight loss and malnutrition, particularly in older adults. The drug is currently in Phase 1 clinical trials for malnutrition and has also been investigated for anorexia. As of March 2025, it remains an investigational new molecular entity with no reported orphan drug status.

Other names: PF 07258669PF07258669PF-07258669

Targets

MC4R (Melanocortin 4 receptor)

Beyond the preview

Go deeper on PF-07258669.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PF-07258669.

Explore the full profile